1.10.2025
Fast Track Initiative, Inc. (FTI) announces its participation in the 800M JPY first closing of Alivexis’s Series D funding round. Alivexis (CEO: Roy S. Kimura, COO: Kazuki Ohno; Headquarters: Tokyo, Japan; formerly known as Modulus Discovery, Inc.) is a pioneering company focused on rapidly and efficiently developing small-molecule therapeutics through advanced computational technologies. This funding brings Alivexis’s total capital raised to approximately 6.66B JPY. Tomo Anzai, Managing Partner of FTI, serves as an External Board of Director of Alivexis.
The newly secured funds will support Alivexis in advancing over 10 proprietary drug discovery programs and accelerating its network-driven research and development efforts. Central to these efforts is ModBind™, the company’s proprietary drug discovery platform, which leverages cutting-edge computational science to revolutionize the speed and precision of drug discovery.
FTI remains dedicated to partnering with groundbreaking companies like Alivexis, supporting advancements in computational drug discovery and accelerating the development of transformative therapies.
About Alivexis
Founded in August 2016, Alivexis, Inc. is a technology-driven drug discovery enterprise with operational foundations in both Japan and the US. By merging state-of-the-art drug discovery platforms with profound knowledge of disease biology and a dynamic global business approach, the company is propelling forward its distinct portfolio of small molecule drugs along with a variety of research and development collaborations. At present, Alivexis is dedicated to swiftly bringing innovative medications to individuals and their families grappling with cancer, both chronic and acute immune-inflammatory conditions, and rare diseases. For more information, visit https://alivexis.com.
About Fast Track Initiative:
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan.
Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/
Media Contact:
For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com
